Vera Therapeutics, Inc. Class A (VERA) Dividend History

Vera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases. The company is dedicated to advancing novel biologics targeting specific pathways to address unmet medical needs, aiming to improve patient outcomes in conditions such as kidney diseases and other chronic inflammatory disorders.

8000 Marina Boulevard, Suite 120, Brisbane, CA, 94005
Phone: 650-770-0077
Website: https://www.veratx.com

Dividend History

Vera Therapeutics, Inc. Class A currently does not pay dividends

Company News

  • Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Vera Therapeutics granted stock options and restricted stock units to 15 new employees, with options to purchase 133,500 shares and RSUs for 73,695 shares, vesting over four years.

    GlobeNewswire Inc.
  • Analysts Can't Get Enough of These Little-Known Biopharma Stocks

    Analysts are bullish on several little-known biopharma stocks, including Kymera Therapeutics, Vera Therapeutics, and Rapport Therapeutics, due to promising drug candidates and strong financial positions.

    Investing.com
    Featured Companies: KYMR RAPP
  • Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market

    The U.S. stock market ended a five-week positive streak as investors feared that slowing economic momentum could impact the earnings outlook for American corporations. The U.S. economy grew at an annualized rate of 1.3% in the first quarter, marking a downward revision from the previous estimate of 1.6%. The Fed's preferred inflation measure remained steady in April, easing some worries about resuming price pressures. Yet, slowing spending and income growth also signaled weakening consumer health, while the Chicago business activity gauge plummeted to its lowest level since May 2020, raising concerns about a potential end-cycle slowdown. The tech sector, as tracked by the Technology Select Sector SPDR Fund (NYSE:XLK), was the worst performer of the week, while utilities, tracked by the Utilities Select Sector SPDR Fund (NYSE:XLU), outperformed ...Full story available on Benzinga.com

    Benzinga
    Featured Companies: COST DIS DJT INTC NFLX NVDA PEP TSLA WMT XLK XLU XOM
  • Could This Stock Be the Next Biotech Buyout?

    Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.

    The Motley Fool
    Featured Companies: VRTX
  • Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex

    Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.

    Zacks Investment Research
    Featured Companies: CRSP VRTX
Page data last updated 07/23/2025 11:40:21 UTC